Current treatment options for retinal angiomatous proliferans (RAP)
- PMID: 19897475
- DOI: 10.1136/bjo.2009.166975
Current treatment options for retinal angiomatous proliferans (RAP)
Abstract
Retinal angiomatous proliferation (RAP) accounts for 12-15% of all patients with neovascular age-related macular degeneration (NV-AMD). However, this subtype is often excluded from clinical trials aimed at assessing the efficacy of various treatment options for NV-AMD. Thus, there are no established protocols for the management of RAP. This review of current literature on RAP compares the outcomes of various treatment options for this condition and highlights the lack of clinical trials and paucity of long-term data on this relatively common condition.
Comment in
-
Maternal drug abuse and ocular morbidity: more than meets the eye?Br J Ophthalmol. 2010 Jun;94(6):671. doi: 10.1136/bjo.2009.174128. Br J Ophthalmol. 2010. PMID: 20508041 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical